ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,344.04
-0.31%
Dow Jones
39,384.92
-0.72%
Gold vs US Dollar
2,343.365
-1.62%
Brent Oil
81.335
-0.24%
Bitcoin
68,193.71
-1.32%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Virax Biolabs Group Ltd (VRAX)

  7. Virax Biolabs Group Ltd (VRAX) News

Virax Biolabs (VRAX)

Virax Biolabs Group Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRAX
DateTimeSourceHeadlineSymbolCompany
25/04/202413:00PR Newswire (US)Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
16/04/202412:30PR Newswire (US)Virax Biolabs to Participate at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
15/03/202420:30PR Newswire (US)Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202422:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202422:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRAXVirax Biolabs Group Ltd
12/01/202412:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
21/12/202312:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
21/12/202312:30PR Newswire (US)Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID PatientsNASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202312:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202312:30PR Newswire (US)Virax Biolabs' CEO James Foster Issues Letter to ShareholdersNASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VRAXVirax Biolabs Group Ltd
14/12/202312:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
14/12/202312:30PR Newswire (US)Virax Biolabs Group Limited Announces 1-for-10 Share ConsolidationNASDAQ:VRAXVirax Biolabs Group Ltd
08/12/202311:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
05/12/202321:06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:VRAXVirax Biolabs Group Ltd
08/11/202321:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
31/10/202320:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
17/10/202321:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VRAXVirax Biolabs Group Ltd
12/10/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
04/10/202312:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
12/09/202312:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
12/09/202312:30PR Newswire (US)Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts WebinarNASDAQ:VRAXVirax Biolabs Group Ltd
01/09/202312:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
01/09/202312:30PR Newswire (US)Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth MomentumNASDAQ:VRAXVirax Biolabs Group Ltd
03/08/202313:39Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
03/08/202312:30PR Newswire (US)Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 BidNASDAQ:VRAXVirax Biolabs Group Ltd
 Showing the most relevant articles for your search:NASDAQ:VRAX

Your Recent History

BTHB
HFTKRW
Hashflow
USOTC
BDFTF
Blender Financial Techno... (GM)
COIN
AIRUSD
LSE
70VX
Paragon 12 C1bs
COIN
CCCBTC
USOTC
NLBS
NutraLife Biosciences (CE)
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved